

George Sgouros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4575435/publications.pdf>

Version: 2024-02-01

70
papers

4,727
citations

117453

34
h-index

98622

67
g-index

71
all docs

71
docs citations

71
times ranked

3370
citing authors

#	ARTICLE	IF	CITATIONS
1	²¹² Pb-conjugated anti-rat HER2/ <i>neu</i> antibody against a <i>neu</i> -N derived murine mammary carcinoma cell line: cell kill and RBE in vitro. International Journal of Radiation Biology, 2022, 98, 1452-1461.	1.0	4
2	I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response. Annals of Nuclear Medicine, 2022, 36, 213-223.	1.2	4
3	Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4382-4393.	3.3	4
4	Preclinical evaluation of ²¹³ Bi- ²²⁵ Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. Journal of Nuclear Medicine, 2021, 62, jnumed.120.256388.	2.8	17
5	Overview of the First NRC Oncology National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2021, 62, 1133-1139.	2.8	5
6	Current Status of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 891-901.	0.4	44
7	Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRC-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 905-912.	0.4	13
8	Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 902-904.	0.4	5
9	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [¹¹¹ In]In-XYMSR-01 for phase I regulatory approval. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 243-250.	0.5	2
10	Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 18-29.	3.3	15
11	ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU, 2021, 21, 1-212.	6.0	52
12	Preclinical Evaluation of ²⁰³ Tl/ ²¹² Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 80-88.	2.8	59
13	Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy. Cancer Research, 2020, 80, 868-876.	0.4	10
14	Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nature Reviews Drug Discovery, 2020, 19, 589-608.	21.5	370
15	Dosimetry, Radiobiology and Synthetic Lethality: Radiopharmaceutical Therapy (RPT) With Alpha-Particle-Emitters. Seminars in Nuclear Medicine, 2020, 50, 124-132.	2.5	29
16	Dosimetric considerations of ^{99m} Tc-MDP uptake within the epiphyseal plates of the long bones of pediatric patients. Physics in Medicine and Biology, 2020, 65, 235025.	1.6	3
17	Specific absorbed fractions and radionuclide S-values for tumors of varying size and composition. Physics in Medicine and Biology, 2020, 65, 235015.	1.6	7
18	Body morphometry appropriate computational phantoms for dose and risk optimization in pediatric renal imaging with Tc- ^{99m} DMSA and Tc- ^{99m} MAG3. Physics in Medicine and Biology, 2020, 65, 235026.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Radium-223 mechanism of action: implications for use in treatment combinations. Nature Reviews Urology, 2019, 16, 745-756.	1.9	71
20	Current pediatric administered activity guidelines for ^{99m}Tc - $^{\text{99m}}\text{Tc}$ -DMSA SPECT based on patient weight do not provide the same task-based image quality. Medical Physics, 2019, 46, 4847-4856.	1.6	7
21	^{68}Ga -DOTATATE PET. Nuclear Medicine Communications, 2019, 40, 920-926.	0.5	8
22	Combined model-based and patient-specific dosimetry for ^{18}F -DCFPyL, a PSMA-targeted PET agent. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 989-998.	3.3	12
23	Comparative Dosimetry for ^{68}Ga -DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors. Journal of Nuclear Medicine, 2018, 59, 1281-1288.	2.8	12
24	Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides. Current Radiopharmaceuticals, 2018, 11, 209-214.	0.3	20
25	Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in ^{124}I PET/CT-Based Dosimetry for ^{131}I Therapy of Metastatic Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 2017, 58, 1146-1154.	2.8	42
26	Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model. Medical Physics, 2017, 44, 272-283.	1.6	8
27	Depth-dependent concentrations of hematopoietic stem cells in the adult skeleton: Implications for active marrow dosimetry. Medical Physics, 2017, 44, 747-761.	1.6	4
28	Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research, 2017, 7, 57.	1.1	35
29	A risk index for pediatric patients undergoing diagnostic imaging with ^{99m}Tc -dimercaptosuccinic acid that accounts for body habitus. Physics in Medicine and Biology, 2016, 61, 2319-2332.	1.6	17
30	(2 <i>S</i>)-(3-(1-Carboxy-5-(4- ^{211}At -Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α -Particle Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 1569-1575.	2.8	101
31	MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative ^{177}Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 2016, 57, 151-162.	2.8	235
32	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Physics, 2015, 2, 5.	1.3	10
33	Preclinical Evaluation of ^{86}Y -Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. Journal of Nuclear Medicine, 2015, 56, 628-634.	2.8	35
34	Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine, 2015, 56, 1401-1407.	2.8	90
35	Strengths and Weaknesses of a Planar Whole-Body Method of ^{153}Sm Dosimetry for Patients with Metastatic Osteosarcoma and Comparison with Three-Dimensional Dosimetry. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 369-379.	0.7	9
36	The Role of Preclinical Models in Radiopharmaceutical Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e121-e125.	1.8	6

#	ARTICLE	IF	CITATIONS
37	Development and evaluation of convergent and accelerated penalized SPECT image reconstruction methods for improved dose-volume histogram estimation in radiopharmaceutical therapy. <i>Medical Physics</i> , 2014, 41, 112507.	1.6	2
38	Radiopharmaceutical therapy in the era of precision medicine. <i>European Journal of Cancer</i> , 2014, 50, 2360-2363.	1.3	16
39	Dosimetry for Radiopharmaceutical Therapy. <i>Seminars in Nuclear Medicine</i> , 2014, 44, 172-178.	2.5	47
40	MIRD Pamphlet No. 24: Guidelines for Quantitative ¹³¹ I SPECT in Dosimetry Applications. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2182-2188.	2.8	125
41	Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?. <i>Antibodies</i> , 2012, 1, 124-148.	1.2	16
42	MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1310-1325.	2.8	293
43	Tumor Dosimetry and Response for ¹⁵³ Sm-Ethylenediamine Tetramethylene Phosphonic Acid Therapy of High-Risk Osteosarcoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 215-224.	2.8	36
44	A bone marrow toxicity model for ²²³ Ra alpha-emitter radiopharmaceutical therapy. <i>Physics in Medicine and Biology</i> , 2012, 57, 3207-3222.	1.6	105
45	Radioimmunotherapy of Solid Tumors: Searching for the Right Target. <i>Current Drug Delivery</i> , 2011, 8, 26-44.	0.8	52
46	Three-dimensional radiobiological dosimetry (3D-RD) with ¹²⁴ I PET for ¹³¹ I therapy of thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 41-47.	3.3	52
47	A Treatment Planning Method for Sequentially Combining Radiopharmaceutical Therapy and External Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1256-1262.	0.4	49
48	An Approach for Balancing Diagnostic Image Quality with Cancer Risk: Application to Pediatric Diagnostic Imaging of ^{99m} Tc-Dimercaptosuccinic Acid. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1923-1929.	2.8	33
49	Modelling and Dosimetry for Alpha-Particle Therapy. <i>Current Radiopharmaceuticals</i> , 2011, 4, 261-265.	0.3	32
50	Pre-therapeutic ¹²⁴ I PET(/CT) dosimetry confirms low average absorbed doses per administered ¹³¹ I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 884-895.	3.3	59
51	Sequential Cytarabine and ¹³¹ I-Particle Immunotherapy with Bismuth-213- ¹²⁵ I-Lintuzumab (HuM195) for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5303-5311.	3.2	234
52	MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry-Standardization of Nomenclature. <i>Journal of Nuclear Medicine</i> , 2009, 50, 477-484.	2.8	633
53	Three-Dimensional Imaging-Based Radiobiological Dosimetry. <i>Seminars in Nuclear Medicine</i> , 2008, 38, 321-334.	2.5	82
54	Antibody-targeted liposomes in cancer therapy and imaging. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 189-204.	2.4	115

#	ARTICLE	IF	CITATIONS
55	MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1884-1899.	2.8	168
56	Three-Dimensional Radiobiologic Dosimetry: Application of Radiobiologic Modeling to Patient-Specific 3-Dimensional Imaging-Based Internal Dosimetry. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1008-1016.	2.8	123
57	Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. <i>Journal of Clinical Investigation</i> , 2007, 117, 2422-2430.	3.9	31
58	Patient-specific dosimetry for ¹³¹ I thyroid cancer therapy using ¹²⁴ I PET and 3-dimensional-internal dosimetry (3D-ID) software. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1366-72.	2.8	196
59	Spheroids of Prostate Tumor Cell Lines. , 2003, 81, 79-88.		0
60	Hematologic Toxicity in Radioimmunotherapy: Dose-Response Relationships for I-131 Labeled Antibody Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 435-443.	0.7	44
61	Therapeutic advantages of Auger electron- over ¹²⁵ I-emitting radiometals or radioiodine when conjugated to internalizing antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 753-765.	3.3	93
62	Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. <i>Medical Physics</i> , 2000, 27, 2150-2164.	1.6	60
63	An ²²⁵ Ac/ ²¹³ Bi generator system for therapeutic clinical applications: construction and operation. <i>Applied Radiation and Isotopes</i> , 1999, 50, 895-904.	0.7	103
64	Therapeutic efficacy and dose-limiting toxicity of auger-electronvs. beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of ¹²⁵ I-vs. ¹³¹ I-labeled CO17-1A in a human colorectal cancer model. , 1998, 76, 738-748.		45
65	Radioimmunotherapy with alpha-emitting nuclides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1341-1351.	3.3	343
66	Mathematical model of 5-[¹²⁵ I]iodo-2-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 1177-1183.	0.4	6
67	Yttrium-90 biodistribution by yttrium-87 imaging: A theoretical feasibility analysis. <i>Medical Physics</i> , 1998, 25, 1487-1490.	1.6	17
68	Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates. <i>Cancer</i> , 1997, 80, 2591-2610.	2.0	98
69	Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. <i>Cancer</i> , 1997, 80, 2591-610.	2.0	42
70	General solution of the radioactive parent-daughter relationship. <i>Medical Physics</i> , 1994, 21, 1739-1740.	1.6	1